{"title":"Caveolin-1的表达可预测切除的胰腺导管腺癌的存活率和复发模式。","authors":"Yuki Hirose, Atsushi Oba, Manabu Takamatsu, Tsuyoshi Hamada, Tsuyoshi Takeda, Tatsunori Suzuki, Aya Maekawa, Yuki Kitano, Shoki Sato, Kosuke Kobayashi, Kojiro Omiya, Yoshihiro Ono, Takafumi Sato, Hiromichi Ito, Takashi Sasaki, Masato Ozaka, Kengo Takeuchi, Naoki Sasahira, Yosuke Inoue, Toshifumi Wakai, Yu Takahashi","doi":"10.1016/j.pan.2024.10.001","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/objective: </strong>Caveolin-1 (Cav1) expressed in cancer cells (cCav1) or cancer-associated fibroblasts (fCav1) exerts either pro- or anti-tumorigenic effects depending on the cancer type or stage of cancer. We aimed to clarify the impact of cCav1 or fCav1 on survival, recurrence patterns, and efficacy of neoadjuvant chemotherapy (NAC) in resected pancreatic ductal adenocarcinoma (PDAC).</p><p><strong>Methods: </strong>Tissue microarrays were constructed including 615 patients who underwent curative resection for PDAC. Cav1 expression was evaluated by immunohistochemistry. Patients were divided into two groups based on Cav1 expression in cancer cells (cCav1<sub>high</sub> vs. cCav1<sub>low</sub>) or cancer-associated fibroblasts (fCav1<sub>high</sub> vs. fCav1<sub>low</sub>).</p><p><strong>Results: </strong>Among all 615 patients, 40.7% were cCav1<sub>high</sub> and 72.7% were fCav1<sub>high</sub>. cCav1<sub>high</sub> was associated with worse overall survival (OS) (p = 0.001) and recurrence-free survival (RFS) (p = 0.001) than cCav1<sub>low</sub>, and was an independent prognostic factor in multivariate analysis of OS and RFS (OS: p = 0.001, hazard ratio [HR] 1.361; RFS: p = 0.001, HR 1.348). Among 596 patients with resectable/borderline resectable PDAC, cCav1<sub>high</sub> patients with NAC showed better OS than those without, while there was no significant difference between cCav1<sub>low</sub> patients with NAC and those without. cCav1<sub>high</sub> was associated with early recurrence (< 6 months) and liver metastasis after resection. Multivariate analysis revealed cCav1<sub>high</sub> as an independent predictor of liver metastasis.</p><p><strong>Conclusions: </strong>cCav1<sub>high</sub> correlated with worse survival, early recurrence, and liver metastasis after resection for PDAC, while NAC improved survival in cCav1<sub>high</sub> patients. The Evaluation of cCav1 status could provide additional information contributing to the personalized management of PDAC.</p>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma.\",\"authors\":\"Yuki Hirose, Atsushi Oba, Manabu Takamatsu, Tsuyoshi Hamada, Tsuyoshi Takeda, Tatsunori Suzuki, Aya Maekawa, Yuki Kitano, Shoki Sato, Kosuke Kobayashi, Kojiro Omiya, Yoshihiro Ono, Takafumi Sato, Hiromichi Ito, Takashi Sasaki, Masato Ozaka, Kengo Takeuchi, Naoki Sasahira, Yosuke Inoue, Toshifumi Wakai, Yu Takahashi\",\"doi\":\"10.1016/j.pan.2024.10.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/objective: </strong>Caveolin-1 (Cav1) expressed in cancer cells (cCav1) or cancer-associated fibroblasts (fCav1) exerts either pro- or anti-tumorigenic effects depending on the cancer type or stage of cancer. We aimed to clarify the impact of cCav1 or fCav1 on survival, recurrence patterns, and efficacy of neoadjuvant chemotherapy (NAC) in resected pancreatic ductal adenocarcinoma (PDAC).</p><p><strong>Methods: </strong>Tissue microarrays were constructed including 615 patients who underwent curative resection for PDAC. Cav1 expression was evaluated by immunohistochemistry. Patients were divided into two groups based on Cav1 expression in cancer cells (cCav1<sub>high</sub> vs. cCav1<sub>low</sub>) or cancer-associated fibroblasts (fCav1<sub>high</sub> vs. fCav1<sub>low</sub>).</p><p><strong>Results: </strong>Among all 615 patients, 40.7% were cCav1<sub>high</sub> and 72.7% were fCav1<sub>high</sub>. cCav1<sub>high</sub> was associated with worse overall survival (OS) (p = 0.001) and recurrence-free survival (RFS) (p = 0.001) than cCav1<sub>low</sub>, and was an independent prognostic factor in multivariate analysis of OS and RFS (OS: p = 0.001, hazard ratio [HR] 1.361; RFS: p = 0.001, HR 1.348). Among 596 patients with resectable/borderline resectable PDAC, cCav1<sub>high</sub> patients with NAC showed better OS than those without, while there was no significant difference between cCav1<sub>low</sub> patients with NAC and those without. cCav1<sub>high</sub> was associated with early recurrence (< 6 months) and liver metastasis after resection. Multivariate analysis revealed cCav1<sub>high</sub> as an independent predictor of liver metastasis.</p><p><strong>Conclusions: </strong>cCav1<sub>high</sub> correlated with worse survival, early recurrence, and liver metastasis after resection for PDAC, while NAC improved survival in cCav1<sub>high</sub> patients. The Evaluation of cCav1 status could provide additional information contributing to the personalized management of PDAC.</p>\",\"PeriodicalId\":19976,\"journal\":{\"name\":\"Pancreatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pancreatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.pan.2024.10.001\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pancreatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.pan.2024.10.001","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma.
Background/objective: Caveolin-1 (Cav1) expressed in cancer cells (cCav1) or cancer-associated fibroblasts (fCav1) exerts either pro- or anti-tumorigenic effects depending on the cancer type or stage of cancer. We aimed to clarify the impact of cCav1 or fCav1 on survival, recurrence patterns, and efficacy of neoadjuvant chemotherapy (NAC) in resected pancreatic ductal adenocarcinoma (PDAC).
Methods: Tissue microarrays were constructed including 615 patients who underwent curative resection for PDAC. Cav1 expression was evaluated by immunohistochemistry. Patients were divided into two groups based on Cav1 expression in cancer cells (cCav1high vs. cCav1low) or cancer-associated fibroblasts (fCav1high vs. fCav1low).
Results: Among all 615 patients, 40.7% were cCav1high and 72.7% were fCav1high. cCav1high was associated with worse overall survival (OS) (p = 0.001) and recurrence-free survival (RFS) (p = 0.001) than cCav1low, and was an independent prognostic factor in multivariate analysis of OS and RFS (OS: p = 0.001, hazard ratio [HR] 1.361; RFS: p = 0.001, HR 1.348). Among 596 patients with resectable/borderline resectable PDAC, cCav1high patients with NAC showed better OS than those without, while there was no significant difference between cCav1low patients with NAC and those without. cCav1high was associated with early recurrence (< 6 months) and liver metastasis after resection. Multivariate analysis revealed cCav1high as an independent predictor of liver metastasis.
Conclusions: cCav1high correlated with worse survival, early recurrence, and liver metastasis after resection for PDAC, while NAC improved survival in cCav1high patients. The Evaluation of cCav1 status could provide additional information contributing to the personalized management of PDAC.
期刊介绍：
Pancreatology is the official journal of the International Association of Pancreatology (IAP), the European Pancreatic Club (EPC) and several national societies and study groups around the world. Dedicated to the understanding and treatment of exocrine as well as endocrine pancreatic disease, this multidisciplinary periodical publishes original basic, translational and clinical pancreatic research from a range of fields including gastroenterology, oncology, surgery, pharmacology, cellular and molecular biology as well as endocrinology, immunology and epidemiology. Readers can expect to gain new insights into pancreatic physiology and into the pathogenesis, diagnosis, therapeutic approaches and prognosis of pancreatic diseases. The journal features original articles, case reports, consensus guidelines and topical, cutting edge reviews, thus representing a source of valuable, novel information for clinical and basic researchers alike.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
